Literature DB >> 3442600

Complete amino-acid sequence and carbohydrate content of the naturally occurring glucosylceramide activator protein (A1 activator) absent from a new human Gaucher disease variant.

T Kleinschmidt1, H Christomanou, G Braunitzer.   

Abstract

Two naturally occurring non-enzymic glucosylceramide activator proteins (A1a and A1b activator) shown previously to be immunochemically not detectable in a new variant of human Gaucher disease (glucosylceramide lipidosis) without glucosylceramidase deficiency, were characterized by amino-acid sequence and carbohydrate content. The complete amino-acid sequence of the A1a activator was determined. The protein consists of 80 amino-acid residues including three disulfide bridges lacking arginine and tryptophan. The molecular mass is 8.95 kDa. About 20% of the polypeptide chain are shorter by two amino-acid residues at the N-terminal end. The A1b activator was characterized by the amino-acid compositions of all tryptic peptides and of the entire protein; sequencing was performed of the regions 1-34 and 42-56. Identical results were obtained for the polypeptide chains of both A1 activators. This suggests that they do not differ in their primary structures which is in agreement with the immunochemical results. The difference between A1a and A1b activator is due to the carbohydrate part. The total amount of 49% carbohydrate in A1a and 76.7% in A1b consists mainly of hexoses. Both chains contain two moles of N-acetylglucosamine per mole protein bound to asparagine in position 22. A comparison of the primary structure of the A1 activator with the sulfatide activator sequence revealed an interesting similarity, especially of the cysteine residues and the carbohydrate-binding asparagine. Sequence homology was also found between a part of the A1 activator sequence and the hemagglutinin neuraminidase of influenza virus as well as to a hypothetical glycoprotein of the Epstein-Barr virus. The comparison with human lysosomal glucosylcerebrosidase showed no sequence similarity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3442600     DOI: 10.1515/bchm3.1987.368.2.1571

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  12 in total

1.  Evidence for two cDNA clones encoding human GM2-activator protein.

Authors:  S Nagarajan; H C Chen; S C Li; Y T Li; J M Lockyer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

Review 2.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

3.  Activator protein deficient Gaucher's disease. A second patient with the newly identified lipid storage disorder.

Authors:  H Christomanou; A Chabás; T Pámpols; A Guardiola
Journal:  Klin Wochenschr       Date:  1989-10-02

4.  Comparative study on glucocerebrosidase in spleens from patients with Gaucher disease.

Authors:  J M Aerts; W E Donker-Koopman; S Brul; S Van Weely; M C Sa Miranda; J A Barranger; J M Tager; A W Schram
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

5.  Saposin A: second cerebrosidase activator protein.

Authors:  S Morimoto; B M Martin; Y Yamamoto; K A Kretz; J S O'Brien; Y Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

6.  Ultrastructural and immunocytochemical study of skin fibroblasts from normal and sialidosis patients.

Authors:  S Igdoura; C Morales; J Tranchemontagne; M Potier
Journal:  Cell Tissue Res       Date:  1994-12       Impact factor: 5.249

7.  Synthesis and characterization of a bioactive 82-residue sphingolipid activator protein, saposin C.

Authors:  S Weiler; W Carson; Y Lee; D B Teplow; Y Kishimoto; J S O'Brien; J A Barranger; J M Tomich
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

8.  Canine GM1-gangliosidosis. A clinical, morphologic, histochemical, and biochemical comparison of two different models.

Authors:  J Alroy; U Orgad; R DeGasperi; R Richard; C D Warren; K Knowles; J G Thalhammer; S S Raghavan
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

9.  Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients.

Authors:  M Horowitz; G Tzuri; N Eyal; A Berebi; E H Kolodny; R O Brady; N W Barton; A Abrahamov; A Zimran
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

10.  Three unique base pair changes in a family with Gaucher disease.

Authors:  N Eyal; N Firon; S Wilder; E H Kolodny; M Horowitz
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.